Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ascend Vitality vs Claya

Ascend Vitality
Graded #307

Lower grade

vs+1.8999999999999986
Claya
Graded #264

Higher grade

The verdict

Claya takes it — 62.8/100 to 60.9/100, but only just.

Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors. Ascend Vitality is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAscend Vitality +8
50
42
Dose & formulationEven
75
75
Clinical oversightClaya +8
74
82
Labs & monitoringClaya +1
52
53
FulfillmentClaya +2
65
67
Contract termsClaya +24
37
61
Ascend Vitality · left barClaya · right bar

The numbers

MetricAscend VitalityClaya
WeighScore60.9/10062.8/100
GradeCC
Scorecard rank#307#264
Semaglutide$199/mo (compounded)$299/mo (compounded)
Tirzepatide$299/mo (compounded)$299/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Ascend Vitality

Graded #307 · C

Strengths

  • Both injectable and needle-free oral tablet forms of semaglutide and tirzepatide
  • LegitScript certified
  • Transparent cash-pay pricing with cancel-anytime subscription
  • Legal entity and address publicly disclosed (Ascend Vitality LLC, Sheridan, WY)

Where it loses points

  • All medications are compounded — FDA does not review compounded drugs for safety/effectiveness
  • No named compounding pharmacy partner disclosed
  • No public state-by-state availability list (homepage cites exclusions: LA, MS, KS, NM, WV)
  • Per-dose/titration pricing not published; only 'starting at' prices shown
Claya

Graded #264 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard